Peptide lexicon
Tesamorelin
Stabilised analogue of growth hormone-releasing hormone (GHRH 1–44) with an N-terminal trans-3-hexenoyl group.
| Substance class | Peptide |
|---|---|
| CAS number | 218949-48-5 |
| Molecular formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molar mass | 5,136 g/mol |
| Synonyms | TH9507, Egrifta |
| PubChem | CID 16137828 |
Structure
Tesamorelin consists of the complete 44-amino-acid sequence of human GHRH, modified at the N-terminus with a trans-3-hexenoyl group. The modification increases stability against degradation by dipeptidyl peptidase-4.
Research and status
As a GHRH receptor agonist, tesamorelin stimulates pulsatile release of growth hormone and IGF-1 in studies. A finished medicinal product is approved in the USA for a specific indication; there is no authorisation in the EU.
Status
WADA lists GHRH and its analogues in category S2.
Literature
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic PerformanceSports Med, 2026 · PMID 41966639 · DOI 10.1007/s40279-026-02437-0
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine PhysiciansAm J Sports Med, 2026 · PMID 41476424 · DOI 10.1177/03635465251357593
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future DirectionsJ Am Acad Orthop Surg Glob Res Rev, 2026 · PMID 41490200 · DOI 10.5435/JAAOSGlobal-D-25-00236
- Tesamorelin2012 · PMID 31644039
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future PerspectivesInt J Mol Sci, 2026 · PMID 42123471 · DOI 10.3390/ijms27093890
